(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Buy Ratings for RE, NOTE, NAK, CPRX - Uncovering Growth Prospects

  • June 21st, 2023
  • 245 views

Citigroup initiated coverage on Everest Re Group, Ltd. (NYSE: RE), a global provider of insurance and reinsurance products, with a Buy rating and set a price target of $406.

Considering the closing price of $352.74 on Tuesday, the assigned price target suggests a potential upside of $53.26 or 15.09% for $RE, based on the investment firm's assessment.

ROTH MKM initiated coverage on FiscalNote Holdings, Inc. (NYSE: NOTE), a technology company specializing in government relationship management solutions, with a Buy rating and a price target of $4.75.

With $NOTE closing at $3.42 on Tuesday, the projected price target indicates a potential upside of $1.33 or 38.88% according to ROTH MKM's analysis.

HC Wainwright & Co. maintained its Buy rating on Northern Dynasty Minerals Ltd. (NYSE American: NAK), a mineral exploration company focused on developing the Pebble Project in Alaska, and raised the price target from $0.80 to $0.90.

Despite closing at $0.22 on Tuesday, the adjusted price target implies a potential upside of $0.68 or 309.09% for $NAK, based on the investment banking firm's evaluation.

Truist Securities maintained its Buy rating on Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company specializing in rare neurological diseases, and raised the price target from $22 to $24.

With $CPRX closing at $12.62 on Tuesday, the revised price target suggests a potential upside of $11.38 or 90.23%, according to the financial services firm's view.

Please note that the potential upsides mentioned for these companies are based on the analysis and recommendations of brokerage firms, investment firms, or analysts, reflecting their outlook on the future performance of each company. Investors should conduct their own research and consider other factors before making any investment decisions.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13